Randomized Trial of Chemotherapy With or Without Venetoclax in Children and Young Adults With Relapsed AML
Led by PedAL BCU, LLC · Updated on 2026-08-24
130
Participants Needed
90
Research Sites
217 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether adding venetoclax to a chemotherapy treatment using fludarabine, cytarabine, and gemtuzumab ozogamicin can improve survival for children, adolescents, and young adults with acute myeloid leukemia AML who are in first relapse but cannot receive more anthracycline drugs, or those in second relapse. This randomized Phase 3 trial focuses on this patient group with a poor prognosis due to chemotherapy-resistant leukemia cells.
Participants receive intensive chemotherapy over two 42-day cycles. In the experimental group, venetoclax is taken orally alongside chemotherapy for the first two cycles, and if clinical benefit is seen but transplant is not possible, maintenance treatment with venetoclax and azacitidine may continue for up to 24 cycles. The control group receives chemotherapy followed by azacitidine alone for maintenance therapy, also up to 24 cycles. Gemtuzumab ozogamicin is given to those whose leukemia cells express CD33.
Participants are closely monitored with assessments after the two induction cycles to decide on stem cell transplantation or maintenance therapy. Researchers measure overall survival for up to 5 years, along with response rates, event-free survival, relapse rates, and treatment safety. Blood samples are taken to study venetoclax levels. The total study participation can last several years to track long-term outcomes and adverse events under the care of the study team.
CONDITIONS
Brief Title
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Research Team
G
Gwen Nichols, MD
M
Michel Zwaan
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Princess Maxima Center for Pediatric Oncology (European Sponsor)
Collaborating Sponsor
How This Trial Compares With Other Options
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Investigational combination adding oral venetoclax to the same chemotherapy backbone
Standard chemotherapy backbone combining fludarabine, cytarabine, and gemtuzumab ozogamicin
role in trial
Experimental arm evaluating venetoclax addition
Control arm without venetoclax
primary use
Investigational salvage combination aiming to improve remission and survival outcomes
Salvage chemotherapy for relapsed AML in pediatric patients
how it is given or performed
Same intravenous chemotherapy plus oral venetoclax added during induction and maintenance
Intravenous fludarabine, cytarabine, and gemtuzumab ozogamicin per protocol
evidence status
Early phase and retrospective data suggest venetoclax addition improves response rates and is tolerable
Standard chemotherapy salvage regimens have varied and long‑term outcomes remain limited
important risks
Venetoclax combinations generally tolerable but associated with cytopenias and infection risk
Intensive cytotoxic chemotherapy carries risk of severe myelosuppression and infection
important limitations
Evidence is from early-phase or retrospective series; phase 3 efficacy and long‑term safety in progress
No universally accepted salvage standard; response durability remains poor
patient impact
Venetoclax addition has led to higher remission and MRD‑negative rates in early studies
Survival outcomes remain unsatisfactory with standard regimens
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 29Days - 21Years
All Genders
Eligibility Criteria
You may qualify if you...
Participants must have enrolled on APAL2020SC prior to this study if in specific regions
Age greater than 28 days and less than 22 years at enrollment
Diagnosis of AML without FLT3/ITD mutation, with either untreated second relapse or first relapse unable to tolerate anthracycline chemotherapy
Performance status of ECOG 0, 1, or 2 (or equivalent Lansky/Karnofsky score)
Fully recovered from prior cancer therapy with specified minimum intervals since last treatments
Adequate renal, liver, and cardiac function as defined by study parameters
Signed informed consent and pediatric assent when required
You will not qualify if you...
Inability to comply with study requirements
Diagnosis of Down syndrome, acute promyelocytic leukemia, or juvenile myelomonocytic leukemia
Current use of other investigational drugs not specified in this trial
Known congenital bone marrow failure syndromes
Allergies to study medications
Active uncontrolled infections
Known hepatitis B, hepatitis C, or HIV infection
Recent use of strong/moderate CYP3A inducers or certain foods before treatment
Pregnancy or breastfeeding; lack of agreed contraception for those of reproductive potential
History of severe veno-occlusive disease or CD33-negative leukemic blasts (excluded from gemtuzumab ozogamicin treatment but eligible for study)
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 to 2 visits for assessments and tests
Treatment Cycles
Duration - Up to 12 weeks
Participants receive two 42-day chemotherapy cycles, with or without venetoclax depending on their group. Gemtuzumab ozogamicin is given to those with CD33-positive leukemia cells. After these cycles, response is assessed to decide on further treatment.
Multiple visits during each 42-day cycle for infusions and monitoring
Maintenance Therapy or Transplant Evaluation
Duration - Up to 2 years
Participants who benefit but cannot proceed to stem cell transplant may receive maintenance therapy with azacitidine alone or combined with venetoclax for up to 24 cycles, based on their study arm.
Regular visits for treatment and monitoring during maintenance
Long-term Follow-up
Duration - Up to 5 years
Participants are monitored for up to 5 years to evaluate overall survival, disease progression, and long-term safety.
Periodic visits for assessments and blood tests
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of Escalating Doses of 211-At-BC8-B10 Followed by Donor Stem Cell Transplant for High-Risk AML, ALL, MDS, or Mixed-Phenotype Acute Leukemia
Phase I Dose Escalation Study of 225Ac-DOTA-Anti-CD38 Daratumumab Added to Fludarabine, Melphalan, and Targeted Total Marrow and Lymphoid Irradiation Before Donor Stem Cell Transplant for High-Risk Leukemia and Myelodysplastic Syndrome
Phase I Study of CLL1 and CD38 Dual-Target CAR-T Cell Injection for Safety and Preliminary Effectiveness in Adults with Relapsed or Refractory Acute Myeloid Leukemia
Study of CD33 CAR-T Cell Therapy for Safety and Effectiveness in Adults with Relapsed or Refractory Acute Myeloid Leukemia
Home-Based CAREFit-BMT Exercise Program to Improve Heart Function in High-Risk Acute Myeloid Leukemia Patients Preparing for Stem Cell Transplant
Study of ASTX030 Azacitidine and Cedazuridine Alone or with Venetoclax for Treatment of Myeloid Neoplasms and AML
Phase III Study of Venetoclax and Revumenib Combination for Treating Minimal Residual Disease in Acute Myeloid Leukemia
Comparing Venetoclax Plus CACAG Versus Standard 37 Chemotherapy in Adults Aged 14 to 75 With Intermediate- or High-Risk Acute Myeloid Leukemia
Study of Ivosidenib with Venetoclax and Azacitidine for Adults with Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia
Phase 1 Dose Escalation and Expansion Study of Orca-Q Engineered Donor Graft in Blood Cancer Patients Undergoing Allogeneic Stem Cell Transplantation
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Venetoclax in combination with cytarabine with or without idarubicin or azacitidine in children, adolescents, and young adults with relapsed or refractory acute myeloid leukaemia (VENAML): a multicentre, phase 1 expansion study.
Dosing of Venetoclax in Pediatric Patients with Relapsed Acute Myeloid Leukemia: Analysis of Developmental Pharmacokinetics and Exposure-Response Relationships.
Mohamed Badawi, Sathej Gopalakrishnan, Benjamin Engelhardt...